secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001370053-24-000026
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio Q1 net loss $43.9M, cash $370M; Phase 2b data for ANB032 by YE2024, $50M royalty monetization
--------------------------------------------------------------------------------

- Q1 2024 net loss $43.9M ($1.64/share) vs $44.3M ($1.58/share) in Q1 2023; revenue $7.2M from Jemperli royalties.
- Cash, cash equivalents, investments total $370.1M (excl. $50M monetization); cash runway through year-end 2026.
- Phase 2b trial for ANB032 (BTLA agonist) in atopic dermatitis enrolling; top-line data expected by year-end 2024.
- Phase 2b trial for rosnilimab (PD-1 agonist) in RA and Phase 2 trial in UC enrolling; top-line data mid-2025 and H1 2026.
- Announced $50M capped non-recourse royalty monetization from Sagard for additional Jemperli royalties; positive Phase 3 imsidolimab results in GPP.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005324000026/0001370053-24-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005324000026/anab-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001370053-24-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer